Sugi Predict

Sugi Predict / Compounds / SCHEMBL6795594

SCHEMBL6795594

SCHEMBL6795594

Nc1cccnc1Nc1cccc(-c2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 1/20 0.49
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ CA9 Q16790 1/20 0.49
▸ EPHX2 P34913 1/20 0.48
▸ PDE10A Q9Y233 1/20 0.46
▸ SYK P43405 4/20 0.45
▸ EGFR P00533 4/20 0.44
▸ ABCG2 Q9UNQ0 3/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ GFER P55789 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ ABL1 P00519 4/20 0.43
▸ PDGFRB P09619 4/20 0.43
▸ FGFR1 P11362 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30269605 1.00 CA12 (0.49) CA12CA1CA2CA9EPHX2
SCHEMBL6797836 0.98 CA12 (0.48) CA12CA1CA2CA9EPHX2
SCHEMBL6798713 0.91 CA12 (0.47) CA12CA1CA2CA9PDE10A
SCHEMBL6798155 0.87 PDE10A (0.44) CA12CA1CA2CA9PDE10A
SCHEMBL2642013 0.87 MEN1 (0.55) CA12CA1CA2CA9SYK
SCHEMBL6797326 0.87 CNR1 (0.46) CA12CA1CA2CA9PDE10A
SCHEMBL19851118 0.85 CA12 (0.63) CA12CA1CA2CA9PDE10A
SCHEMBL1859867 0.85 CA12 (0.63) CA12CA1CA2CA9PDE10A
SCHEMBL6793161 0.83 CTSC (0.47) CA12CA1CA2CA9PDE10A
SCHEMBL6799440 0.83 CA12 (0.43) CA12CA1CA2CA9PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3936512-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS Universal Display Corporation (US) 2022-01-12 — — EP disclosed
EP-3424935-B1 IMIDAZOPYRAZINYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORP (US) 2021-08-11 — — EP disclosed
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2021-02-18 — — US disclosed
US-10873038-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2020-12-22 — — US disclosed
US-20190109287-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2019-04-11 — — US disclosed
EP-3424935-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS Universal Display Corporation (US) 2019-01-09 — — EP disclosed
US-9972793-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2018-05-15 — — US disclosed
US-9972793-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2018-05-15 — — US disclosed
US-20150021590-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2015-01-22 — — US disclosed
US-8883322-B2 Pyridyl carbene phosphorescent emitters UNIVERSAL DISPLAY CORPORATION (US) 2014-11-11 — — US disclosed
WO-2012121936-A2 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORPORATION (US) 2012-09-13 — — WO disclosed
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORPORATION (US) 2012-09-13 — — US disclosed
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS UNIVERSAL DISPLAY CORPORATION (US) 2012-09-13 — — US disclosed
US-6727245-B2 4-(HETERO)ARYL-3-OXO-3,4-DIHYDROPYRIDO(2,3-B)PYRAZINE DERIVATIVES; PROPHYLACTIC OR THERAPEUTIC TREATMENT OF PHOSPHODIESTERASE IV AND TUMOR NECROSIS FACTOR MEDIATED DISEASES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-04-27 — — US disclosed
EP-0770079-B1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2003-02-12 — — EP disclosed
US-20020107251-A1 Heterobicyclic derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-08-08 — — US disclosed
US-6426345-B1 PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-07-30 — — US disclosed
EP-0920867-A1 Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-06-09 — — EP disclosed
EP-0770079-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-05-02 — — EP disclosed
WO-1996001825-A1 HETEROBICYCLIC DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-01-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210050530-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NUDC, NCL, NDC1 CA12 4525/4885CA1 4639/4885CA2 3829/4885
US-10873038-B2 Organic electroluminescent materials and devices NUDC, NCL, NDC1 CA12 4525/4885CA1 4639/4885CA2 3829/4885
US-20120228583-A1 PYRIDYL CARBENE PHOSPHORESCENT EMITTERS PAICS, PIR, NUDC CA12 4166/4885CA1 4484/4885CA2 2994/4885
US-20190109287-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES NUDC, NCL, NDC1 CA12 4525/4885CA1 4639/4885CA2 3829/4885
US-20020107251-A1 Heterobicyclic derivatives ARSA, ARRB1, SULT2A1 CA12 2455/4885CA1 3131/4885CA2 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.